Immunotherapy in Sepsis: State of the Art and the Need for Predictive Biomarkers

Background/Objectives: Sepsis involves a heterogeneous and dynamic immune response, characterized by the coexistence of hyperinflammation and immunosuppression. This complexity limits the efficacy of immunomodulatory therapies in unselected populations and supports the development of biomarker-guided precision immunotherapy. Methods: A narrative review of publications indexed in PubMed between 2019 and 2026 was conducted. Clinical trials, systematic reviews, and meta-analyses investigating immunotherapeutic strategies in sepsis were prioritized. Additional relevant publications were identified through reference screening. Results: Current approaches target hyperinflammation, restore innate and adaptive immunity, or modulate humoral responses. Anakinra and biomarker-guided strategies have shown promising signals in selected subgroups, whereas studies of nangibotide, interferon-γ, interleukin-7, granulocyte-macrophage colony-stimulating factor, immune checkpoint inhibitors, thymosin α1, and immunoglobulins have yielded heterogeneous results. Despite improvements in immune parameters or organ function reported with some interventions, a consistent mortality benefit has not been established across the general sepsis population. Most available biomarkers provide prognostic or phenotypic information rather than validated predictions of treatment response. Conclusions: Precision immunotherapy represents a promising direction in sepsis management, but its clinical translation remains challenging. Distinguishing prognostic from predictive biomarkers and integrating clinical, cellular, molecular, and functional parameters may improve patient stratification. Dynamic immune monitoring and multimarker classification could support individualized treatment selection and timing. However, prospective validation of treatment–biomarker interactions, standardized assessment methods, and robust evidence of meaningful clinical benefit are essential before widespread implementation.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-19
DOI
https://doi.org/10.3390/jcm15229080
Primary Topic
Sepsis Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immunotherapy in Sepsis: State of the Art and the Need for Predictive Biomarkers

Giulia Pignataro, Antonio Gasbarrini, Benedetta Simeoni, Andrea Piccioni et al.
Journal of Clinical Medicine
Sepsis Diagnosis and Treatment
article

Immunotherapy in Sepsis: State of the Art and the Need for Predictive Biomarkers

Giulia Pignataro, Antonio Gasbarrini, Benedetta Simeoni, Andrea Piccioni, Marcello Covino, Antonio Landi, Marcello Candelli, Francesco Franceschi, Fabio Spagnuolo, Alberto Valentini
article en

Abstract

Background/Objectives: Sepsis involves a heterogeneous and dynamic immune response, characterized by the coexistence of hyperinflammation and immunosuppression. This complexity limits the efficacy of immunomodulatory therapies in unselected populations and supports the development of biomarker-guided precision immunotherapy. Methods: A narrative review of publications indexed in PubMed between 2019 and 2026 was conducted. Clinical trials, systematic reviews, and meta-analyses investigating immunotherapeutic strategies in sepsis were prioritized. Additional relevant publications were identified through reference screening. Results: Current approaches target hyperinflammation, restore innate and adaptive immunity, or modulate humoral responses. Anakinra and biomarker-guided strategies have shown promising signals in selected subgroups, whereas studies of nangibotide, interferon-γ, interleukin-7, granulocyte-macrophage colony-stimulating factor, immune checkpoint inhibitors, thymosin α1, and immunoglobulins have yielded heterogeneous results. Despite improvements in immune parameters or organ function reported with some interventions, a consistent mortality benefit has not been established across the general sepsis population. Most available biomarkers provide prognostic or phenotypic information rather than validated predictions of treatment response. Conclusions: Precision immunotherapy represents a promising direction in sepsis management, but its clinical translation remains challenging. Distinguishing prognostic from predictive biomarkers and integrating clinical, cellular, molecular, and functional parameters may improve patient stratification. Dynamic immune monitoring and multimarker classification could support individualized treatment selection and timing. However, prospective validation of treatment–biomarker interactions, standardized assessment methods, and robust evidence of meaningful clinical benefit are essential before widespread implementation.

Journal of Clinical MedicineVol. 15(22)
Università Cattolica del Sacro Cuore (IT), Agostino Gemelli University Polyclinic (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Sepsis Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon